12 extractive question-and-answer pairs built from Heavy Menstrual Bleeding, published by icmr.gov.in. The source is a 1-page publication. Source-evidenced topics include tranexamic acid, oc pills, hysterectomy, nsaids, progestogens, lng ius, ormeloxifene, ablative techniques. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. Question types in the export: 9 factual, 2 list, 1 summary. 3 of the 12 pairs (25.0%) ask explanatory questions; the remaining 9 are factual or table-based questions. 100.00% of rows pass the corpus quality gate.
This dataset contains 12 extractive question-and-answer pairs derived from a publication on heavy menstrual bleeding by icmr.gov.in. It covers topics such as hormonal therapy, diagnostic procedures, and referral criteria. The answers are verbatim excerpts from the source document, ensuring accuracy. The dataset highlights conservative management approaches, diagnostic protocols, and conditions requiring advanced interventions. All rows were reviewed, and the dataset provides detailed insights into clinical recommendations for managing heavy menstrual bleeding.
Browse more economy datasets, including other records from the same source when available.
Explore Economy datasets1725952331_psychiatry_all - Question and Answer Dataset
Economy · 176 rows
ICMR Standard Treatment Workflow (STW) SUPRACONDYLAR FRACTURE OF HUMERUS IN CHILDREN - Question and Answer Dataset
Economy · 22 rows
1726569102_ophthalmology_all - Question and Answer Dataset
Health · 77 rows
1725952349_ent - Question and Answer Dataset
Health · 178 rows
Annual Report 2015-16 by agriwelfare.gov.in - Question and Answer Dataset
Economy · 1K+ rows
Higher Education in India - Question and Answer Dataset
Economy · 1.5K+ rows
Gender Policy of NABARD - Question and Answer Dataset
Economy · 14 rows
ICAR Annual Report 2025-26 - Question and Answer Dataset
Economy · 1.1K+ rows
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/www-icmr-gov-in-a64a76e3ed2eb8d6fea00e2a8971b57c/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("www-icmr-gov-in-a64a76e3ed2eb8d6fea00e2a8971b57c")
df.head()First 10 of 12 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_document | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| How should hormone therapy be administered for a total of 4-6 cycles? | orally daily in divided doses from the fifth day of the cycle for three weeks and repeated in a cyclical manner | Management as per the condition • Norethisterone (max daily dose 40 mg) OR • Medroxyprogesterone acetate (max daily dose 40 mg) • Hormone therapy should be given orally daily in divided doses from the fifth day of the cycle for three weeks and repeated in a cyclical manner for total of 4-6 cycles of treatment • As an alternative LNG IUS should be consid- ered • Age • Parity, Abortions, Infertility • Detailed Menstrual History Including Irregularities • Other Medical Illness: Thyroid Disorder, Hypertension, Bleeding Disorders, Heart Disease, Liver Disorders, • IUCD Use, Tubectomy • Drug History • Family history-Malignancies, Bleeding disorders CONSERVATIVE MANAGEMENT FOR HMB MUST BE ATTEMPTED BEFORE DEFINITIVE SURGICAL PROCEDURE ESPECIALLY IN YOUNGER WOMEN | 162 | summary | 0.970 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | Management as per the condition • Norethisterone (max daily dose 40 mg) OR • Medroxyprogesterone acetate (max daily dose 40 mg) • Hormone therapy should be given orally daily in divided doses from the fifth day of the cycle for three weeks and repeated in a cyclical manner for total of 4-6 cycles of treatment • As an alternative LNG IUS should be consid- ered • Age • Parity, Abortions, Infertility • Detailed Menstrual History Including Irregularities • Other Medical Illness: Thyroid Disorder, Hypertension, Bleeding Disorders, Heart Disease, Liver Disorders, • IUCD Use, Tubectomy • Drug | 1 | page=1,block=111 | 0.700 | valid |
| What medical conditions should be considered during the management of this condition? | Thyroid Disorder, Hypertension, Bleeding Disorders, Heart Disease, Liver Disorders | Management as per the condition • Norethisterone (max daily dose 40 mg) OR • Medroxyprogesterone acetate (max daily dose 40 mg) • Hormone therapy should be given orally daily in divided doses from the fifth day of the cycle for three weeks and repeated in a cyclical manner for total of 4-6 cycles of treatment • As an alternative LNG IUS should be consid- ered • Age • Parity, Abortions, Infertility • Detailed Menstrual History Including Irregularities • Other Medical Illness: Thyroid Disorder, Hypertension, Bleeding Disorders, Heart Disease, Liver Disorders, • IUCD Use, Tubectomy • Drug History • Family history-Malignancies, Bleeding disorders CONSERVATIVE MANAGEMENT FOR HMB MUST BE ATTEMPTED BEFORE DEFINITIVE SURGICAL PROCEDURE ESPECIALLY IN YOUNGER WOMEN | 480 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | Management as per the condition • Norethisterone (max daily dose 40 mg) OR • Medroxyprogesterone acetate (max daily dose 40 mg) • Hormone therapy should be given orally daily in divided doses from the fifth day of the cycle for three weeks and repeated in a cyclical manner for total of 4-6 cycles of treatment • As an alternative LNG IUS should be consid- ered • Age • Parity, Abortions, Infertility • Detailed Menstrual History Including Irregularities • Other Medical Illness: Thyroid Disorder, Hypertension, Bleeding Disorders, Heart Disease, Liver Disorders, • IUCD Use, Tubectomy • Drug | ||||
| What treatment is suggested for reassurance and improving hemoglobin levels? | Reassurance • Hematinics | General • Pallor (Mild/Moderate/Severe) • Calculate BMI • Pulse rate and BP measurement • Lymphadenopathy Systemic • CVS, RS and hepatosplenomegaly, • Mass abdomen INVESTIGATIONS • Hemoglobin • CBC with periph- eral smear • BT / CT • LFT • Reassurance • Hematinics • Tranexamic acid during episode of heavy bleeding (Injection/Oral) • Tranexamic acid+ Mefenemic acid- if pain is associated | 240 | list | 0.740 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | General • Pallor (Mild/Moderate/Severe) • Calculate BMI • Pulse rate and BP measurement • Lymphadenopathy Systemic • CVS, RS and hepatosplenomegaly, • Mass abdomen INVESTIGATIONS • Hemoglobin • CBC with periph- eral smear • BT / CT • LFT • Reassurance • Hematinics • Tranexamic acid during episode of heavy bleeding (Injection/Oral) • Tranexamic acid+ Mefenemic acid- if pain is associated | 1 | page=1,block=103 | 0.700 | valid |
| What diagnostic procedure is suggested for hyperplasia without atypia in heavy menstrual bleeding? | Do endometrial sampling and send for histopathological examination | -Tranexamic acid - OC Pills Consider hysterectomy If no relief 3-6 months - NSAIDS - Tranexamic Acid - OC Pills - Progestogens - LNG IUS - Ormeloxifene - Ablative Techniques If no relief, Refer to higher centre - NSAIDS - Tranexamic acid - Combined OC Pills - Progestogens - LNG IUS Secretory/Proliferative Phase endometrium without hyperplasia Hyperplasia with atypia/ malignancy Hyperplasia without atypia Do endometrial sampling and send for histopathological examination If no relief or recurrence Refer to higher centre Refer to higher centre Refer to higher centre Refer to higher centre Married <40 years Married >40 years Post Menopausal No hyperplasia or benign hyperplasia < 40 years > 40 years Adolescents Thickened endometrium Atypical Hyperplasia Adnexal mass Fibroids & polyps, and adenomyosis No structural abnormality Structural abnormality Standard Treatment Workflow (STW) HEAVY MENSTRUAL BLEEDING (HMB) | 408 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | -Tranexamic acid - OC Pills Consider hysterectomy If no relief 3-6 months - NSAIDS - Tranexamic Acid - OC Pills - Progestogens - LNG IUS - Ormeloxifene - Ablative Techniques If no relief, Refer to higher centre - NSAIDS - Tranexamic acid - Combined OC Pills - Progestogens - LNG IUS Secretory/Proliferative Phase endometrium without hyperplasia Hyperplasia with atypia/ malignancy Hyperplasia without atypia Do endometrial sampling and send for histopathological examination If no relief or recurrence Refer to higher centre Refer to higher centre Refer to higher centre Refer to higher centre | ||||
| What hemoglobin level or condition necessitates referral to a higher center? | If Hb <7g/dL or acute ongoing blood loss refer to higher centre | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 85 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 1 | page=1,block=31 | 0.700 | valid |
| What is the recommended hormonal therapy duration for adolescents with heavy menstrual bleeding? | to continue for 6 months | No Abnormality Abnormality No Relief Adolescents Supportive treatment Do USG - Levonorgestrel- releasing intrauterine system (LNG IUS) Progesterones Hormonal therapy to continue for 6 months In absence of obvious cause - NSAIDS - Tranexamic Acid - OC Pills - Progestogens Adolescents Supportive Treatment -Tranexamic acid - OC Pills No Relief Endometrial thickness < 12 mm ET>12mm or High Risk for endometrial cancer* • Hemoglobin • SIS/Hysteroscopy MRI • CBC with peripheral smear • BT /CT, LFT, RFT • ABO and Rh typing • Thyroid function test • USG of Abdomen & Pelvis INVESTIGATIONS In selected cases • ABO and Rh typing • TSH • USG of Abdomen & Pelvis INVESTIGATIONS • Hemoglobin • CBC with peripheral smear • BT/CT | 166 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | No Abnormality Abnormality No Relief Adolescents Supportive treatment Do USG - Levonorgestrel- releasing intrauterine system (LNG IUS) Progesterones Hormonal therapy to continue for 6 months In absence of obvious cause - NSAIDS - Tranexamic Acid - OC Pills - Progestogens Adolescents Supportive Treatment -Tranexamic acid - OC Pills No Relief Endometrial thickness < 12 mm ET>12mm or High Risk for endometrial cancer* • Hemoglobin • SIS/Hysteroscopy MRI • CBC with peripheral smear • BT /CT, LFT, RFT • ABO and Rh typing • Thyroid function test • USG of Abdomen & Pelvis INVESTIGATIONS In selected | ||||
| What should be done for women of reproductive age before excluding pregnancy? | Exclude pregnancy in all women of reproductive age group after appropriate consent | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 2 | factual | 0.570 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 1 | page=1,block=31 | 0.700 | valid |
| Under what circumstances is blood transfusion recommended? | Blood transfusion if Hb <7g/dL or acute ongoing blood loss | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 213 | factual | 0.530 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | * Exclude pregnancy in all women of reproductive age group after appropriate consent If Hb <7g/dL or acute ongoing blood loss refer to higher centre If Hb <7g/dL or acute ongoing blood loss refer to higher centre Blood transfusion if Hb <7g/dL or acute ongoing blood loss ** Amongst progestogens Norethisterone provides the best hemostasis | 1 | page=1,block=31 | 0.700 | valid |
| What is the next step if conservative modalities do not provide relief for heavy menstrual bleeding? | Refer to higher centre | Conservative modalities - Tranexamic Acid - Progestogens - LNG IUS - Ormeloxifene - Ablative techniques No Relief Refer to higher centre - NSAIDs - Tranexamic acid - Progestogens** OC Pills Contraception desired Contraception not desired Refer to higher centre Refer to Higher centre Any Abnormality Women of Reproductive Age Age > 40 years | 114 | factual | 0.490 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | Conservative modalities - Tranexamic Acid - Progestogens - LNG IUS - Ormeloxifene - Ablative techniques No Relief Refer to higher centre - NSAIDs - Tranexamic acid - Progestogens** OC Pills Contraception desired Contraception not desired Refer to higher centre Refer to Higher centre Any Abnormality Women of Reproductive Age Age > 40 years | 1 | page=1,block=59 | 0.700 | valid |
| What is the recommended action for heavy menstrual bleeding with hyperplasia with atypia or malignancy? | Refer to higher centre | -Tranexamic acid - OC Pills Consider hysterectomy If no relief 3-6 months - NSAIDS - Tranexamic Acid - OC Pills - Progestogens - LNG IUS - Ormeloxifene - Ablative Techniques If no relief, Refer to higher centre - NSAIDS - Tranexamic acid - Combined OC Pills - Progestogens - LNG IUS Secretory/Proliferative Phase endometrium without hyperplasia Hyperplasia with atypia/ malignancy Hyperplasia without atypia Do endometrial sampling and send for histopathological examination If no relief or recurrence Refer to higher centre Refer to higher centre Refer to higher centre Refer to higher centre Married <40 years Married >40 years Post Menopausal No hyperplasia or benign hyperplasia < 40 years > 40 years Adolescents Thickened endometrium Atypical Hyperplasia Adnexal mass Fibroids & polyps, and adenomyosis No structural abnormality Structural abnormality Standard Treatment Workflow (STW) HEAVY MENSTRUAL BLEEDING (HMB) | 188 | factual | 0.490 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1768382529_updatedheavymenstrualbleeding.pdf | -Tranexamic acid - OC Pills Consider hysterectomy If no relief 3-6 months - NSAIDS - Tranexamic Acid - OC Pills - Progestogens - LNG IUS - Ormeloxifene - Ablative Techniques If no relief, Refer to higher centre - NSAIDS - Tranexamic acid - Combined OC Pills - Progestogens - LNG IUS Secretory/Proliferative Phase endometrium without hyperplasia Hyperplasia with atypia/ malignancy Hyperplasia without atypia Do endometrial sampling and send for histopathological examination If no relief or recurrence Refer to higher centre Refer to higher centre Refer to higher centre Refer to higher centre |
Read straight from the file — download or use the API URL for the full dataset.
| 1 |
| page=1,block=111 |
| 0.700 |
| valid |
| 1 |
| page=1,block=0 |
| 0.700 |
| valid |
| 1 |
| page=1,block=74 |
| 0.700 |
| valid |
| 1 |
| page=1,block=0 |
| 0.700 |
| valid |